Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry)

NCT07197775 · tracked via the Priya Life Science USA tracker

Sponsor

Endogenex, Inc.

Phase

Observational

Started

2026-03-11

Last updated

2026-07-01

Condition(s) studied

Type 2 Diabetes Mellitus (T2DM)Type2DiabetesDiabetes Mellitus, Type 2Type 2 DiabetesDiabetes

Study summary

This registry is designed to collect long-term data and support ongoing post-market surveillance of real-world data for the Endogenex System.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Type 2 diabetes * Have been treated with the Endogenex System * Consented to participate in the Endogenex PULSE Registry Exclusion Criteria: * Unwilling or unable to attend study visits * Unwilling or unable to provide medical records to study sites

Primary outcome measure(s)

Incidence of adverse events — Through 5 years
Incidence of device-related and/or procedure-related adverse events

Trial sites (4)

Facility	City	Region
Care Access	Quincy	Massachusetts
Care Access	Raleigh	North Carolina
Care Access	Houston	Texas
St Vincent's Hospital Melbourne	Fitzroy	Victoria

More Endogenex, Inc. trials in the USA

Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study Enrolling by invitation

Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes Active, not recruiting

Other trials for the same condition

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) Recruiting

Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature Recruiting

CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin Active, not recruiting

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease Recruiting

A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07197775 on ClinicalTrials.gov ↗ ← All trials in the USA